Source:

Yu QT et al. Poster 1667. Presented at: Annual Regional Anesthesiology and Acute Pain Medicine Meeting; May 13-15, 2021; Lake Buena Vista, Florida.

Disclosures: Yu reports no relevant disclosures.
June 10, 2021
1 min watch
Save

VIDEO: Baseline laxative use does not affect Relistor outcomes in opioid-induced constipation

Source:

Yu QT et al. Poster 1667. Presented at: Annual Regional Anesthesiology and Acute Pain Medicine Meeting; May 13-15, 2021; Lake Buena Vista, Florida.

Disclosures: Yu reports no relevant disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video exclusive, Qi T. Yu, DO, from Loma Linda University Health, discussed how laxatives at baseline impacted the outcomes of subcutaneous Relistor in patients with advanced illness and opioid-induced constipation.

Yu presented the research at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting.

“In patients with advanced illness and opioid-induced constipation, the use of [Relistor (methylnaltrexone, Salix Pharmaceuticals)] was really helpful because it increased the proportion of patients [who] were able to have a spontaneous bowel movement within 4 hours and 24 hours when they are not able to have that spontaneous bowel movement with a baseline laxative use,” she said.

Yu noted baseline laxative use did not affect the use of methylnaltrexone itself. Methylnaltrexone did not reduce efficacy of opioids and did not cause any adverse events.